Complications after surgery for benign prostatic enlargement: a population-based cohort study in Ontario, Canada

BMJ Open. 2019 Dec 30;9(12):e032170. doi: 10.1136/bmjopen-2019-032170.

Abstract

Objectives: To examine the complication rates after benign prostatic enlargement (BPE) surgery and the effects of age, comorbidity and preoperative medical therapy.

Design: A retrospective, population-based cohort study using linked administrative data.

Setting: Ontario, Canada.

Participants: 52 162 men≥66 years undergoing first BPE surgery between 1 January 2003 to 31 December 2014.

Intervention: Medical therapy preoperatively and surgery for BPE.

Primary and secondary outcome measures: The primary outcome was overall 30-day postoperative complication rates. Secondary outcomes included BPE-specific event rates (bleeding, infection, obstruction, trauma) and non-BPE specific event rates (cardiovascular, pulmonary, thromboembolic and renal). Multivariable analysis examined the association between preoperative medical therapy and postoperative complication rates.

Results: The 30-day overall complication rate after BPE surgery was 2828 events/10 000 procedures and increased annually over the study period. Receipt of preoperative α-blocker monotherapy (relative rate (RR) 1.05; 95% CI 1.00 to 1.09; p=0.033) and antithrombotic medications (RR 1.27; 95% CI 1.22 to 1.31; p<0.0001) was associated with increased complication rates. Among the ≥80-year-old group, the rate of complications increased by 39% from 2003 to 2014 (RR 1.39; 95% CI 1.21 to 1.61; p<0.0001). The mean duration of medical and conservative management increased by a mean of 2.1 years between 2007 and 2014 (p<0.0001 for trend).

Conclusions: Thirty-day complication rates after BPE surgery have increased annually between 2003 and 2014. Preoperative medical therapy with alpha blockers or antithrombotics was independently associated with higher rates of complications. Over this time, the duration of conservative therapy also increased.

Keywords: 5-alpha reductase inhibitors; adrenergic alpha-antagonists; benign prostatic hyperplasia; postoperative complications; postoperative haemorrhage; urinary retention.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic alpha-Antagonists / adverse effects*
  • Aged
  • Aged, 80 and over
  • Databases, Factual
  • Fibrinolytic Agents / adverse effects*
  • Humans
  • Linear Models
  • Male
  • Multivariate Analysis
  • Ontario
  • Postoperative Complications / epidemiology*
  • Preoperative Care / adverse effects
  • Preoperative Care / methods
  • Prostatic Hyperplasia / surgery*
  • Retrospective Studies
  • Time Factors

Substances

  • Adrenergic alpha-Antagonists
  • Fibrinolytic Agents